These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 30670436)

  • 1. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.
    Xhemali X; Smith JR; Kebriaei R; Rice SA; Stamper KC; Compton M; Singh NB; Jahanbakhsh S; Rybak MJ
    J Antimicrob Chemother; 2019 Jan; 74(1):82-86. PubMed ID: 30260409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
    Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
    Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
    Lepak A; Marchillo K; VanHecker J; Andes D
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7833-6. PubMed ID: 26392492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
    Werth BJ; Steed ME; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
    Vidaillac C; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Guzek A; Rybicki Z; Tomaszewski D
    Indian J Med Microbiol; 2018; 36(1):119-120. PubMed ID: 29735840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
    Kebriaei R; Rice SA; Singh NB; Stamper KC; Nguyen L; Sheikh Z; Rybak MJ
    J Antimicrob Chemother; 2020 Oct; 75(10):2894-2901. PubMed ID: 32591820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.